A successful induction of CD8+ T-cell response to MAGE by demethylating treatment against acute myeloid leukemia and myelodysplasia was shown in 2010 [14] and, subsequently, DAC was demonstrated to successfully enhance the MAGE-A4 specific T-cell immune response in patients with relapsed Hodgkin lymphoma in 2011 [15]. This evidence concerns the gene CD8A and Hodgkins lymphoma.